Wednesday, September 30, 2026

Alnylam highlights Amvuttra through ATTR-CM patient story

Alnylam is presenting Amvuttra (vutrisiran) in a US patient communication format called “Play by Play”. The campaign centers on Pete Shaw, a former professional football player living with ATTR cardiomyopathy. The content combines personal storytelling with disease education, treatment information and safety messaging.

The format also features Shaw’s wife and caregiver, Kari, and his cardiologist, Dr. Mohan. Alnylam states that Shaw and Dr. Mohan were compensated for taking part. That disclosure is important for assessing the material as branded patient communication.

A patient story for a complex rare disease

The website describes ATTR amyloidosis as a progressive disease in which transthyretin misfolds and can form deposits in organs and tissues. In ATTR-CM, the heart is a key site of involvement. The campaign also notes that symptoms may appear in other parts of the body before a cardiac diagnosis is made, including musculoskeletal problems.

Shaw’s story is used to illustrate the path from initially unclear symptoms to cardiology evaluation and treatment. The tone is patient-focused, while the structure remains closely tied to brand and disease education. For pharma marketers, the notable element is the mix of testimonial, caregiver perspective and physician explanation.

How Amvuttra is positioned

The materials describe Amvuttra as a prescription medicine for adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, intended to reduce heart-related death, hospital stays and urgent visits. It is also listed for adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.

The treatment is administered by a healthcare professional once every three months as a subcutaneous injection. Alnylam presents Amvuttra as a TTR silencer that acts in the liver to reduce transthyretin production. The site also emphasizes a dosing schedule of four injections per year.

Safety information remains central

The campaign includes extensive safety information. A key warning is that Amvuttra can lower vitamin A levels. Patients are advised in the material to take the vitamin A supplement recommended by their doctor and not to exceed that amount.

Low vitamin A levels may affect vision, including night vision. The most commonly listed side effects include pain in the arms or legs, joint pain, shortness of breath and low vitamin A levels. The materials also direct patients to report adverse events to the US Food and Drug Administration.

What it means for pharma communication

“Play by Play” shows how manufacturers can combine emotional storytelling with explanatory content in rare disease communication. The campaign addresses patients, caregivers and the broader care environment. At the same time, the messaging remains anchored in indication, administration and risk information.

From a B2B perspective, the execution is an example of how patient experience, disease awareness and brand positioning can be brought together in a digital format. The use of a former professional athlete adds recognition value, while the physician perspective gives the disease and treatment narrative additional structure.